5-LOX Inhibitor Species Hanisms distinct from bortezomib. Cancer Cell 2005; eight: 4079. 22 Demchenko YN, Glebov Okay, Zingone
Hanisms distinct from bortezomib. Cancer Cell 2005; 8: 4079. 22 Demchenko YN, Glebov Okay, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and / or option NF-kappaB pathway PPARα Compound activation in numerous myeloma. Blood 2010; 115: 35412. 23 Iwai K. Various ubiquitin signaling in NF-jB activation. Trends Cell Biol 2012; 22: 3554. 24 Wang J, Ray PS, Sim MS et al. FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-jB signaling. Oncogene 2012; 31: 479802. 25 Selimovic D, Porzig BB, El-Khattouti A et al. Bortezomib / proteasome inhibitor triggers each apoptosis and autophagy-dependent pathways in melanoma cells. Cell Signal 2013; 25: 3088. 26 Nadiminty N, Tummala R, Liu C et al. NF-jB2 / p52 induces resistance to enzalutamide in prostate cancer: function of androgen receptor and its variants. Mol Cancer Ther 2013; 12: 16297. 27 Liu H, Westergard TD, Cashen A et al. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias by way of MLL-AF4. Cancer Cell 2014; 25: 5302. 28 Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS341 inhibits growth, induces apoptosis, and overcomes drug resistance in human various myeloma cells. Cancer Res 2001; 61: 3071. 29 Richardson PG, Barlogie B, Berenson J et al. A phase 2 research of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 26097. 30 Kuhn DJ, Chen Q, Voorhees PM et al. Potent action of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical versions of several myeloma. Blood 2007; 110: 32810. 31 Chauhan D, Tian Z, Zhou B et al. In vitro and in vivo selective antitumor action of a novel orally bioavailable proteasome inhibitor MLN9708 towards a number of myeloma cells. Clin Cancer Res 2011; 17: 53111. 32 Heinrich Pc, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Ideas of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem J 2003; 374: ten. 33 Catlett-Falcone R, Landowski TH, Oshiro MM et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 1055. 34 Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is usually a critical survival aspect for a number of myeloma. Blood 2002; 99: 18853. 35 L S, Yang J, Song X et al. Level mutation of your proteasome beta5 subunit u gene is an crucial mechanism of bortezomib resistance in bortezomibselected variants of Jurkat T cell lymphoblastic lymphoma / leukemia line. J Pharmacol Exp Ther 2008; 326: 4231. 36 Kuhn DJ, Berkova Z, Jones RJ et al. Targeting the insulin-like development factor-1 receptor to overcome bortezomib resistance in preclinical designs of various myeloma. Blood 2012; 120: 32600. 37 Wang J, Hendrix A, Hernot S et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in numerous myeloma cells. Blood 2014; 124: 5555.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 288, NO. 42, pp. 30019 0028, October 18, 2013 2013 by the American Society for Biochemistry and Molecular Biology, Inc. Published inside the U.S.A.Arylsulfatase K, a Novel Lysosomal Sulfatase*Received for publication, July four, 2013, and revised kind, August twenty, 2013 Published, JBC Papers in Press, August 28, 2013, DOI ten.1074/jbc.M113.Elena Marie Wiegmann1, Eva Westendorf1, Ina Kalus, Thomas H. Pringle Torben L ke, and Thomas Dierks2 In the Department of Chemistry, Biochemistry I, Bielefeld University, 33615 Bielefeld, Germany and also the �Sperling F.
